Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	25^th April 2023

2. INTERESTS AND SHORT POSITIONS

a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,439,894 (1.941%)		501 (0.000%)
(2) Derivatives (other than options)	-		-
(3) Options and agreements to purchase/sell	284,900 (0.125%)		1,301,000 (0.569%)
Total	4,724,794 (2.065%)		1,301,501 (0.569%)

b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Purchase	24,662	110.50
Purchase	199	110.47
Purchase	3,859	110.56
Purchase	249	110.80
Purchase	100	110.43
Purchase	3,001	110.53
Purchase	1,291	110.51
Purchase	6,659	110.61
Purchase	3,901	110.55
Purchase	1,339	110.46
Purchase	269	110.58
Sale	149	110.58
Purchase	100	110.62
Purchase	386	110.49
Purchase	229	110.48
Purchase	2,601	110.57
Purchase	1,051	110.70
Purchase	200	110.68
Purchase	1,120	110.64
Purchase	260	110.67
Purchase	300	110.71
Purchase	50	110.60
Purchase	50	110.51
Sale	151	110.58
Purchase	51	110.54
Purchase	45	110.69
Purchase	36	110.45
Purchase	31	110.44
Sale	2,135	110.58
Purchase	1,920	110.60
Purchase	1,091	110.50
Sale	78	110.50
Purchase	8,033	110.47
Sale	100	110.47
Purchase	784	110.56
Sale	200	110.56
Purchase	31	110.80
Purchase	9,200	110.78
Purchase	600	110.45
Purchase	403	110.43
Purchase	918	110.53
Purchase	100	110.41
Purchase	694	110.51
Sale	200	110.51
Purchase	280	110.61
Purchase	46	110.46
Purchase	257	110.58
Purchase	2,000	110.52
Purchase	463	110.74
Purchase	400	110.57
Purchase	200	110.83
Purchase	675	110.75
Purchase	272	110.64
Sale	1,120	110.64
Purchase	542	110.54
Purchase	199	110.67
Purchase	100	110.89
Purchase	710	110.66
Purchase	186	110.82
Purchase	228	110.59
Purchase	100	110.69
Purchase	100	110.86
Purchase	1	110.81
Purchase	103	110.38
Purchase	16,626	110.50
Purchase	155	110.56
Purchase	180	110.51
Purchase	316	110.61
Purchase	20	110.55
Purchase	3	110.65
Purchase	486	110.58
Purchase	45	110.62
Purchase	56	110.52
Purchase	3,571	110.49
Purchase	10	110.48
Purchase	875	110.57
Purchase	112	110.64
Purchase	160	110.54
Purchase	60	110.63
Purchase	15	110.59
Purchase	45	110.60

b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

c) Options transactions in respect of existing relevant securities

i) Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price (USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	26^th April 2023
Contact name	Sirina Kumar
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,100	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	262,400	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	55,400	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	2,900	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	221,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	254,200	100.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,600	105.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	10,900	105.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	100,000	115.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	46,600	85.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	155,000	100.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	200,000	100.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Purchased	4,200	112.00	American	5/5/2023
IE00BQPVQZ61	Call Option	Purchased	4,200	113.00	American	5/5/2023
IE00BQPVQZ61	Put Option	Purchased	3,400	112.00	American	5/5/2023
IE00BQPVQZ61	Put Option	Purchased	3,400	113.00	American	5/5/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1086917

Time of Receipt (offset from UTC): 20230426T135102+0100